Citations

Clear

1792 citation(s) found for "Stephanie".

International Lung Cancer Consortium: Pooled Analysis of Sequence Variants in DNA Repair and Cell Cycle Pathways
Hung, Rayjean J., Risch, Angela , Popanda, Odilia , Haugen, Aage, Zienolddiny, Shanbeh , Benhamou, Simone , Bouchardy, Christine , Lan, Qing , Spitz, Margaret R., Wichmann, H. E., Vineis, Paolo , Matullo, Giuseppe , Kiyohara, Chikako , Zhang, Zuo‐Feng , Pezeshki, Benhnaz, Harris, Curtis C. , Mechanic, Leah E. , Seow, Adeline , Ng, Daniel , Szeszenia‐Dąbrowska, Neonila, Заридзе, Давид , Lissowska, Jolanta , Rudnai, Péter, Fabiánová, Eleonóra , Mateș, Dana , Foretová, Lenka , Janout, Vladimí­r , Bencko, Vladimír , Caporaso, Neil E. , Chen, Chu , Duell, Eric J. , Goodman, Gary E. , Field, John K. , Houlston, Richard S. , Landi, Maria Teresa , McLaughlin, John, Schwartz, Ann G. , Stücker, Isabelle, Tajima, Kazuo, Matsuo, Keitaro , Thun, Michael J., Andrew, Angeline S. , Monnier, Stéphanie, Brennan, Paul , Hung, Rayjean J. , Hung, Rayjean J., Christiani, David C. , Marchand, Loı̈c Le , Hong, Yun‐Chul , Lazarus, Philip J. , Muscat, Joshua E. , McLaughlin, John, Shen, Hongbing , Yang, Ping , Wiencke, John K. , Boffetta, Paolo , Houlston, Richard S , Lissowska, Jolanta , Duell, Eric J , Hung, Rayjean J , Field, John K , Matsuo, Keitaro , Mates, Dana , Matullo, Giuseppe , Risch, Angela , Zienolddiny, Shanbeh

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3081-3089

10.1158/1055-9965.epi-08-0411 | PMID 18990748 Get It

Abstract Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3081–9)
Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression
Li, Liang , Kalari, Krishna R. , Jenkins, Gregory D. , Batzler, Anthony , Safgren, Stephanie L. , Ames, Matthew M. , Schaid, Daniel J. , Wang, Liewei , Fridley, Brooke L. , Hildebrandt, Michelle A.T. , Kalari, Krishna R , Li, Liang , Safgren, Stephanie L

Mayo Clinic

Cancer Research | August 29, 2008 | Volume: 68 | Issue: 17 | Pages: 7050-7058

10.1158/0008-5472.can-08-0405 | PMID 18757419 Get It

Abstract Two cytidine analogues, gemcitabine (dFdC) and 1-β-d-arabinofuranosylcytosine (AraC), show significant therapeutic effect in a variety of cancers. However, response to these drugs varies widely. Evidence from tumor biopsy samples shows that expression levels for genes involved in the cytidine transport, metabolism, and bioactivation pathway contribute to this variation in response. In the present study, we set out to test the hypothesis that variation in gene expression both within and outside of this “pathway” might influence sensitivity to gemcitabine and AraC. Specifically, Affymetrix U133 Plus 2.0 GeneChip and cytotoxicity assays were performed to obtain basal mRNA expression and IC50 values for both drugs in 197 ethnically defined Human Variation Panel lymphoblastoid cell lines. Genes with a high degree of association with IC50 values were involved mainly in cell death, cancer, cell cycle, and nucleic acid metabolism pathways. We validated selected significant genes by performing real-time quantitative reverse transcription-PCR and selected two representative candidates, NT5C3 (within the pathway) and FKBP5 (outside of the pathway), for functional validation. Those studies showed that down-regulation of NT5C3 and FKBP5 altered tumor cell sensitivity to both drugs. Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues. [Cancer Res 2008;68(17):7050–8]
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.
P2‐172: Wild‐type mouse tau transgenic model: Halfway to a complete AD model
Adams, Stephanie J. , Innes, Amy, Randle, Suzanne J. , Yu, Cindy, Hutton, Mike, Dugger, Brittany N. , Crook, Richard , McGowan, Eileen , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2008.05.1246 Get It

Intermittent Hemodialysis Versus Continuous Renal Replacement Therapy for Acute Renal Failure in the Intensive Care Unit: An Observational Outcomes Analysis
Rauf, Anis Abdul, Long, Kirsten Hall , Anderson, Stephanie S., Swaminathan, Lalithapriya, Albright, Robert C. , Gajic, Ognjen

Mayo Clinic

Journal of Intensive Care Medicine | May 12, 2008 | Volume: 23 | Issue: 3 | Pages: 195-203

10.1177/0885066608315743 | PMID 18474503 Get It

Background: Studies have failed to show a survival difference between intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT). Comparative cost analyses are limited and fail to control for differences in patient disease severity and comorbid conditions. The authors retrospectively estimated clinical and economic outcomes associated with CRRT and IHD among critically ill patients experiencing acute renal failure (ARF) in 2 tertiary care hospitals in Rochester, Minnesota, between January 1, 2000, and December 12, 2001. Methods: 161 critically ill patients requiring dialysis for ARF were analyzed. Patient demo-graphics, comorbid conditions, ARF etiology, mode of renal replacement therapy (RRT), renal recovery, and survival were abstracted from medical chart. APACHE II scores at dialysis initiation were calculated. Administrative data tracked length of stay (LOS) and direct medical costs from initiation of RRT to death or intensive care unit (ICU) and hospital discharge. Multivariate modeling was used to adjust outcomes for baseline differences. Results: 84 (52%) of the patients received CRRT and 77 (48%) received IHD. CRRT-treated patients were younger (58 vs 65 years), less likely male (58% vs 77%), had higher APACHE II scores (32 vs 27) with a higher incidence of sepsis (46% vs 30%) and respiratory disease (56% vs 39%), and were less likely to have chronic renal insufficiency (32% vs 49%). With adjustment for differences in baseline patient characteristics, the RRT method did not affect the likelihood of renal recovery, in-hospital survival, or survival during follow-up. Mean adjusted ICU LOS was 9.5 days shorter for IHD-treated than CRRT-treated patients ( P < .001), and the adjusted mean difference in hospital and total costs associated with ICU stay was $56 564 and $60 827, in favor of IHD ( P < .001). Mean adjusted total costs through hospital discharge were $93 611 and $140 733 among IHD-treated and CRRT-treated patients, respectively ( P < .001). Conclusions: This observational study suggests that costs may significantly differ by mode of RRT despite similar severity-adjusted patient outcomes. Future prospective comparisons of renal replacement modalities will need to include both clinical and economic outcomes.
Timing of Androgen Deprivation Therapy and its Impact on Survival After Radical Prostatectomy: A Matched Cohort Study
Siddiqui, Sameer , Boorjian, Stephen A. , Inman, Brant A. , Bagniewski, Stephanie M., Bergstralh, Eric J., Blute, Michael L., Inman, Brant A

Mayo Clinic

Journal of Urology | March 19, 2008 | Volume: 179 | Issue: 5 | Pages: 1830-1837

10.1016/j.juro.2008.01.022 | PMID 18353378 Get It

Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, Chitta Ranjan , Wang, Enfeng , Katarya, Aaron, Lau, Julie S., Dutta, Shamit K., Muders, Michael H. , Wang, Shanfeng , Buhrow, Sarah A. , Safgren, Stephanie L. , Yaszemski, Michael J. , Ames, Matthew M. , Bhattacharya, Resham , Reid, Joel M. , Mukherjee, Priyabrata , Mukhopadhyay, Debabrata , Safgren, Stephanie L

Mayo Clinic

Cancer Research | March 13, 2008 | Volume: 68 | Issue: 6 | Pages: 1970-1978

10.1158/0008-5472.can-07-6102 | PMID 18339879 Get It

Abstract One of the key challenges in anticancer therapy is the toxicity and poor bioavailability of the anticancer drugs. Nanotechnology can play a pivotal role by delivering drugs in a targeted fashion to the malignant cells that will reduce the systemic toxicity of the anticancer drug. In this report, we show a stepwise development of a nanoparticle-based targeted delivery system for in vitro and in vivo therapeutic application in pancreatic cancer. In the first part of the study, we have shown the fabrication and characterization of the delivery system containing gold nanoparticle as a delivery vehicle, cetuximab as a targeting agent, and gemcitabine as an anticancer drug for in vitro application. Nanoconjugate was first characterized physico-chemically. In vitro targeting efficacy, tested against three pancreatic cancer cell lines (PANC-1, AsPC-1, and MIA Paca2) with variable epidermal growth factor receptor (EGFR) expression, showed that gold uptake correlated with EGFR expression. In the second part, we showed the in vivo therapeutic efficacy of the targeted delivery system. Administration of this targeted delivery system resulted in significant inhibition of pancreatic tumor cell proliferation in vitro and orthotopic pancreatic tumor growth in vivo. Tumor progression was monitored noninvasively by measuring bioluminescence of the implanted tumor cells. Pharmacokinetic experiments along with the quantitation of gold both in vitro and in vivo further confirmed that the inhibition of tumor growth was due to targeted delivery. This strategy could be used as a generalized approach for the treatment of a variety of cancers characterized by overexpression of EGFR. [Cancer Res 2008;68(6):1970–8]
Characterization of gp120 Hydrolysis by IgA Antibodies from Humans without HIV Infection
Planque, Stephanie , Mitsuda, Yukie, Taguchi, Hiroaki , Salas, María , Morris, Mary-Kate, Nishiyama, Yasuhiro , Kyle, Robert, Okhuysen, Pablo C. , Hunter, Robert L. , Sheppard, Haynes W., Hanson, Carl V. , Paul, Sudhir, Escobar, Miguel Antonio

Mayo Clinic

AIDS Research and Human Retroviruses | December 26, 2007 | Volume: 23 | Issue: 12 | Pages: 1541-1554

10.1089/aid.2007.0081 | PMID 18160012 Get It

Increased Optical Magnification From 2.5× to 4.3× With Technical Modification Lowers the Positive Margin Rate in Open Radical Retropubic Prostatectomy
Magera, James S., Inman, Brant A. , Slezak, Jeffrey M., Bagniewski, Stephanie M., Sebo, Thomas J., Myers, Robert P., Inman, Brant A

Mayo Clinic

Journal of Urology | December 5, 2007 | Volume: 179 | Issue: 1 | Pages: 130-135

10.1016/j.juro.2007.08.128 | PMID 17997426 Get It